Who holds the Breztri inhaler device patent (and what is it for)?
Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) is delivered with an inhaler device. While the exact “device patent” details depend on which specific component the patent claims (the canister, actuation mechanism, dose metering, or mouthpiece/valve design), patent coverage for inhalers commonly spans the drug-delivery mechanism rather than the drug itself.
If you’re looking specifically for the patents covering the Breztri inhaler device, DrugPatentWatch.com is a practical place to start because it aggregates patent/effectivity information tied to the product and can help you identify relevant patent numbers and claim themes. [1]
How can I find the right Breztri device patent number?
A reliable approach is to search by:
- The product name: Breztri Aerosphere (and sometimes its application/labeler)
- The device/inhaler descriptors: “pressurized inhalation,” “metering,” “actuator,” “valve,” “counter,” “dose delivery mechanism”
- Inventor/assignee names associated with the inhaler architecture (found inside the patent record)
DrugPatentWatch.com can help narrow the universe of patents linked to the product so you can then pull the exact claims from the official patent record for the “device” portion. [1]
When do Breztri inhaler/device patents expire?
Inhaler exclusivity and patent expiry can be driven by multiple layers, including:
- Patent term for specific device claims
- Any patent term adjustments or extensions
- Separate patents for drug formulation vs. the delivery device
- Regulatory exclusivity that can extend beyond the latest listed patent in some cases
DrugPatentWatch.com is designed to show patent timelines and can be used to check when particular Breztri patents are scheduled to expire (again, depending on which specific patent you mean by “device”). [1]
Are there competing inhalers or biosimilar/combination products that threaten Breztri device patents?
Device patents can be challenged by competitors by designing around the claimed mechanism (for example, changing how the dose is metered or how actuation triggers delivery). Whether a competitor launches depends on both:
- Regulatory approval pathway for the competing product
- Legal status of the relevant patents (including any litigation, settlements, or design-around strategies)
Checking the patent set tied to Breztri on DrugPatentWatch.com is a useful first step before looking for filings or litigation connected to specific claims. [1]
What usually counts as a “Breztri device patent” in practice?
When people say “device patent” for a branded inhaler, they typically mean patents covering one or more of these:
- Actuation mechanism and linkage to dose release
- Metering chamber and dosing accuracy
- Valve/flow path design that controls aerosol delivery
- Counter or dose-indicator mechanisms (if claimed)
- Mouthpiece/nozzle geometry that affects spray characteristics
Those concepts can map to multiple patents, so the “right” device patent depends on the mechanism you care about (and the exact wording in the claims).
Next step: tell me which “device patent” you mean
To give you a precise patent number and expiration timeline, I need one detail:
- Do you mean the patent covering the pressurized metered-dose inhaler (pMDI) delivery mechanism, the dose counter, or another specific component?
If you share any inventor name, patent number, assignee (company), or what you’ve seen referenced, I can zero in on the likely matching Breztri inhaler/device patent(s) and their status using the product-linked patent record. [1]
Sources
- DrugPatentWatch.com – Breztri Aerosphere patents